-
公开(公告)号：US08026364B2
公开(公告)日：2011-09-27
申请号：US12750420
申请日：2010-03-30
申请人： Sapna S. Shah , Anandan Palani , Xianhai Huang , Dong Xiao , Sunil Paliwal , Hon-Chung Tsui , Michelle Laci Wrobleski , Ashwin U. Rao , Cheng Wang , Neng-Yang Shih
发明人： Sapna S. Shah , Anandan Palani , Xianhai Huang , Dong Xiao , Sunil Paliwal , Hon-Chung Tsui , Michelle Laci Wrobleski , Ashwin U. Rao , Cheng Wang , Neng-Yang Shih
IPC分类号： C07F7/02 , C07D215/12 , C07D215/16 , C07D213/02 , C07D211/02 , C07D405/00
CPC分类号： C07D401/04 , A61K31/4178 , A61K31/451 , A61K31/4523 , A61K31/454 , A61K31/4545 , A61K31/573 , A61K45/06 , C07D211/56 , C07D211/60 , C07D211/66 , C07D211/76 , C07D413/04 , C07D417/04 , C07D498/20
摘要： A compound having the general structure shown in Formula I: or pharmaceutically acceptable salt and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
摘要翻译： 具有式I所示的一般结构的化合物或其药学上可接受的盐和/或溶剂合物可用于治疗由NK1受体介导的疾病或病症，例如各种生理疾病，症状或疾病，包括呕吐，抑郁，焦虑和咳嗽 。
-
公开(公告)号：US20110152259A1
公开(公告)日：2011-06-23
申请号：US13033895
申请日：2011-02-24
申请人： Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying R. Huang , Robert G. Aslanian , Brain A. McKittrick , Syliva J. Degrado
发明人： Anandan Palani , Jing Su , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Haiqun Tang , Jun Qin , Ying R. Huang , Robert G. Aslanian , Brain A. McKittrick , Syliva J. Degrado
IPC分类号： A61K31/5377 , C07D491/052 , A61K31/519 , C07D413/14 , A61P3/00 , A61P7/00 , A61P35/00 , A61P11/00
CPC分类号： C07D491/04 , C07D471/04
摘要： The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译： 本发明提供式（I）的化合物及其药学上可接受的盐，溶剂合物，酯和互变异构体，其中：Q选自：和L选自：药物组合物，其包含一种或多种 更多的式（I）化合物和使用式（I）化合物的方法。
-
公开(公告)号：US20100297128A1
公开(公告)日：2010-11-25
申请号：US12747011
申请日：2008-12-09
IPC分类号： A61K39/395 , C07D487/04 , C07D471/04 , C07D473/32 , A61K31/5025 , A61K31/437 , A61K31/52 , A61K31/519 , A61P25/28
CPC分类号： C07D487/04 , C07D471/04
摘要： This invention provides novel compounds that are modulators of gamma secretase. The compounds have the formula [Chemical formula should be inserted here as it appears on abstract in electronic form.] Also disclosed are methods of modulating gamma secretase activity and methods of treating Alzheimer's disease using the compounds of formula (I).
摘要翻译： 本发明提供了作为γ分泌酶调节剂的新型化合物。 化合物具有式[化学式应该插入在此，其以电子形式的摘要出现。]还公开了使用式（I）化合物调节γ-分泌酶活性的方法和治疗阿尔茨海默氏病的方法。
-
公开(公告)号：US07737155B2
公开(公告)日：2010-06-15
申请号：US11771538
申请日：2007-06-29
申请人： Anandan Palani , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Jun Qin , Ying R. Huang , Robert G. Aslanian
发明人： Anandan Palani , Dong Xiao , Xianhai Huang , Ashwin U. Rao , Xiao Chen , Jun Qin , Ying R. Huang , Robert G. Aslanian
IPC分类号： C07D491/052 , A61K31/519 , A61P9/00 , A61P25/00 , A61P33/00 , A61P29/00 , A61P1/00 , A61P3/10
CPC分类号： C07D491/04 , C07D471/04
摘要： The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).
摘要翻译： 本发明提供式（I）的化合物及其药学上可接受的盐，溶剂合物，酯和互变异构体，其中：Q选自：和L选自：药物组合物，其包含一种或多种 更多的式（I）化合物和使用式（I）化合物的方法。
-
65.发明申请Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia 失效杂环作为治疗血脂异常的烟酸受体激动剂公开(公告)号：US20070173495A1
公开(公告)日：2007-07-26
申请号：US11654137
申请日：2007-01-17
申请人： Anandan Palani , Jun Qin , Dong Xiao , Ying R. Huang , Xiao Chen , Zhidan Liu , Sylvia J. Degrado , Robert G. Aslanian , Xianhai Huang
发明人： Anandan Palani , Jun Qin , Dong Xiao , Ying R. Huang , Xiao Chen , Zhidan Liu , Sylvia J. Degrado , Robert G. Aslanian , Xianhai Huang
IPC分类号： A61K31/551 , A61K31/519 , C07D491/02
CPC分类号： C07D491/04
摘要： A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.
摘要翻译： 具有式（I）的一般结构的化合物或其药学上可接受的盐，溶剂合物，酯或互变异构体可用于治疗疾病，病症或病症如代谢综合征和血脂异常。
-
公开(公告)号：US20060258665A1
公开(公告)日：2006-11-16
申请号：US11291363
申请日：2005-12-01
申请人： Dong Xiao , Anandan Palani , Cheng Wang , Hon-Chung Tsui , Xianhai Huang , Sapna Shah , Ashwin Rao , Xiao Chen , Sunil Paliwal , Neng-Yang Shih
发明人： Dong Xiao , Anandan Palani , Cheng Wang , Hon-Chung Tsui , Xianhai Huang , Sapna Shah , Ashwin Rao , Xiao Chen , Sunil Paliwal , Neng-Yang Shih
IPC分类号： A61K31/498 , C07D487/04
CPC分类号： C07D471/08
摘要： A compound having the general structure shown in Formula (I): or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
摘要翻译： 具有式（I）所示的一般结构的化合物或其药学上可接受的盐和/或溶剂化物可用于治疗由NK 1受体介导的疾病或病症，例如各种生理紊乱，症状或 疾病包括呕吐，抑郁，焦虑和咳嗽。
-
公开(公告)号：US10442819B2
公开(公告)日：2019-10-15
申请号：US15532549
申请日：2015-12-01
申请人： Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , J. Michael Ellis , Sara Esposite , Qingmei Hong , Chunhui Huang , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Ryan D. Otte , Dann L. Parker, Jr. , Michael Reutershan , Nunzio Sciammetta , Pengcheng P. Shao , David L. Sloman , Feroze Ujjainwalla , Catherine White , Zhicai Wu , Yang Yu , Kake Zhao , Craig Gibeau , Tesfaye Biftu , Purakkattle Biju , Lei Chen , Joshua Close , Peter H. Fuller , Xianhai Huang , Min K. Park , Valdimir Simov , David J. Witter , Hongjun Zhang
发明人： Christian Fischer , Stephane L. Bogen , Matthew L. Childers , Francesc Xavier Fradera Llinas , J. Michael Ellis , Sara Esposite , Qingmei Hong , Chunhui Huang , Alexander J. Kim , John W. Lampe , Michelle R. Machacek , Daniel R. McMasters , Ryan D. Otte , Dann L. Parker, Jr. , Michael Reutershan , Nunzio Sciammetta , Pengcheng P. Shao , David L. Sloman , Feroze Ujjainwalla , Catherine White , Zhicai Wu , Yang Yu , Kake Zhao , Craig Gibeau , Tesfaye Biftu , Purakkattle Biju , Lei Chen , Joshua Close , Peter H. Fuller , Xianhai Huang , Min K. Park , Valdimir Simov , David J. Witter , Hongjun Zhang
IPC分类号： A61K31/351 , A61K31/4353 , A61K31/5355 , A61K31/551 , C07D471/04 , C07D471/14 , C07D498/08 , C07D471/08 , C07D498/04 , C07D498/10 , A01N43/00
摘要： The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers.
-
公开(公告)号：US20170267695A1
公开(公告)日：2017-09-21
申请号：US15531771
申请日：2015-12-10
申请人： Phieng Siliphaivanh , David L. Sloman , David Witter , Umar Faruk Mansoor , Joseph Kozlowski , Ziping Liu , Jianmin Fu , Zhilong Wan , Wei Liu , Yimin Qian , Xianhai Huang
发明人： Phieng Siliphaivanh , David L. Sloman , David Witter , Umar Faruk Mansoor , Joseph Kozlowski , Ziping Liu , Jianmin Fu , Zhilong Wan , Wei Liu , Yimin Qian , Xianhai Huang
IPC分类号： C07D498/18 , C07D471/22 , C07D471/18
CPC分类号： C07D498/18 , A61K31/437 , A61K31/444 , C07D471/18 , C07D471/22
摘要： The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a method of inhibiting ERK2 in a patient in need of such treatment comprising administering to said patient an effective amount of at least one compound of Formula (I). The invention also provides a method for treating cancer in a patient in need of such treatment, said method comprising administering to said patient an effective amount of at least one compound of Formula (I).
-
公开(公告)号：US20150258074A1
公开(公告)日：2015-09-17
申请号：US14431485
申请日：2013-09-26
申请人： Kevin J. WILSON , David J. WITTER , Matthew H. DANIELS , Angie R. ANGELES , Phieng SILIPHAIVANH , David L. SLOMAN , Brendan O'BOYLE , Danielle FALCONE , Catherine WHITE , Ron FERGUSON , Wei ZHOU , Kathryn LIPFORD , Umar Faruk MANSOOR , Salem FEVRIRE , Xianhai HUANG , Ravi KURUKULASURIYA , Judson E. RICHARD , Shuyi TANG , Christopher BOYCE , Joseph KOZLOWSKI , Raman Kumar BAKSHI , Ganesh Babu UNAKARAN , Merck Sharp & Dohme Corp.
发明人： Kevin J. Wilson , David J. Witter , Matthew H. Daniels , Angie R. Angeles , Phieng Siliphaivanh , David Sloman , Brendan O'Boyle , Danielle Falcone , Catherine White , Ron Ferguson , Wei Zhou , Kathryn Lipford , Umar Faruk Mansoor , Salem Fevrier , Xianhai Huang , Ravi Kurukulasuriya , Judson E. Richard , Shuyi Tang , Christopher Boyce , Joseph Kozlowski , Raman Kumar Bakshi , Ganesh Babu Karunakaran
IPC分类号： A61K31/437 , A61K45/06 , A61K31/4545 , C07D471/04
CPC分类号： A61K31/437 , A61K31/4545 , A61K45/06 , C07D471/04
摘要： Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
摘要翻译： 公开了具有吡唑并吡啶基结构的式（1.0）的ERK抑制剂及其药学上可接受的盐。 还公开了使用式（1.0）化合物治疗癌症的方法。
-
公开(公告)号：US08754216B2
公开(公告)日：2014-06-17
申请号：US13245403
申请日：2011-09-26
申请人： Sapna S. Shah , Anandan Palani , Xianhai Huang , Dong Xiao , Sunil Paliwal , Hon-Chung Tsui , Michelle Laci Wrobleski , Ashwin U. Rao , Cheng Wang , Neng-Yang Shih
发明人： Sapna S. Shah , Anandan Palani , Xianhai Huang , Dong Xiao , Sunil Paliwal , Hon-Chung Tsui , Michelle Laci Wrobleski , Ashwin U. Rao , Cheng Wang , Neng-Yang Shih
IPC分类号： C07F7/02 , C07D215/12 , C07D215/16 , C07D213/02 , C07D405/00
CPC分类号： C07D401/04 , A61K31/4178 , A61K31/451 , A61K31/4523 , A61K31/454 , A61K31/4545 , A61K31/573 , A61K45/06 , C07D211/56 , C07D211/60 , C07D211/66 , C07D211/76 , C07D413/04 , C07D417/04 , C07D498/20
摘要： A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.
摘要翻译： 具有式I所示的一般结构的化合物或其药学上可接受的盐和/或溶剂合物可用于治疗由NK1受体介导的疾病或病症，例如各种生理疾病，症状或疾病，包括呕吐，抑郁，焦虑和咳嗽 。
-
-
-
-
-
-
-
-
-
搜索结果
74 条记录 (耗时 0.06 秒)
